Travere Therapeutics (NASDAQ:TVTX) climbed ~27% in the premarket on Wednesday after the company said that the FDA has ...

If approved, FILSPARI would be the first medication indicated for FSGS, a rare and serious kidney disorder driven by ...

Travere Therapeutics TVTX announced that the FDA, following further review of the supplemental new drug application (sNDA) ...

Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Travere Therapeutics, Inc. (TVTX) shares are trading higher on Wednesday after the company announced that it was informed by ...

FDA cuts liver monitoring for Filspari to every three months and drops embryo-fetal toxicity REMS. Travere awaits FDA’s 2026 decision on Filspari for FSGS. Want to trade this news? Get access to the ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) said that the U.S. Food and Drug Administration granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgA ...

Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2i New mechanistic data to show ...

(RTTNews) - Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in focal ...

The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...